JAHA: The effect of Rugli's net on patients with normal heart failure with normal blood cell scores associated with diabetes.

Randomized controlled trials have reported that sodium-glucose co-transport protein 2 inhibitors have the effect of reducing hospitalization in patients with heart failure, but their efficacy in patients with normal blood cell scores (HFpEF) is unclear.
, a study published in JAHA, a major journal in the field of cardiovascular disease, assessed the efficacy of sodium glucose co-transport protein 2 inhibitor Ruglie in patients with type 2 diabetes and HFpEF.
the researchers conducted a multicenter, open, randomized, controlled trial that compared the efficacy of 2.5mg ruglio and 0.2mg voligtose per day at 1:1 randomization in HFpEF patients with diabetes (left amortary hemorrhage fractions of 45% and BNP concentrations of 35pg/mL) at 1:1 randomization.
outcome of the study was a difference in baseline BNP levels between the two drugs after 12 weeks.
the study included a total of 173 HFpEF patients with diabetes.
of these patients, 83 were assigned to Ruglie net treatment and 82 patients were treated with voglipo sugar.
there was no significant difference in the decrease in BNP concentration between the baseline and 12 weeks of treatment between the two groups.
the average BNP value to the baseline value in week 12 was 0.79 and the Voglibo sugar group was 0.87 (percentage change was -9.0% vs. -1.9%; Ruglie's net-to-Voglibo sugar change ratio is 0.93; 95% CI is 0.78-1.10; and P-0.26).
the results showed no significant difference in the degree of BNP reduction after 12 weeks of treatment for Ruglie net and voglipo sugar in HFpEF patients with type 2 diabetes.
.